Roche and Genentech Strike Deal With Surmodics For Biodegradable Microparticle Drug Delivery System for Lucentis
October 7, 2009
Submit Comments
Roche and Genentech have signed a licensing agreement with SurModics, Inc., to take advantage of SurModics’ proprietary biodegradable microparticle drug delivery system, to develop and commercialize a sustained delivery formulation for Lucentis in treating age-related macular degeneration. The agreement also provides Roche and Genentech with the opportunity to develop additional compounds using the sustained drug delivery system for the treatment of other ophthalmic diseases.
For the full story, see the SurModics news release.
Also, for more on this, see my new writeup in my online Journal.
Comments (0)
Trackbacks
Print this post
Filed in Industry News, Macular Degeneration, New Technologies, Research, Retina
You might also enjoy...
- Is Iluvien From Alimera Sciences the Future of Ophthalmic Drug Delivery?
- Icon Biosciences Starting New Trials of Sustained Release Drug Delivery for Post-Op Cataract Patients
- Intravitreal Drug Delivery System Okay for Diabetic Macular Edema
- pSivida Announces Positive Results From The Two Phase 3 FAME™ Trials of Iluvien in Patients With Diabetic Macular Edema
- Can Lucentis Improve Vision in Patients with Diabetic Macular Edema?
Comments
Jump down to form below to submit your own comments
